Saturday, 31 October 2026European Markets

NEXT BIOMETRICS GP Stock Went Up By Over 27% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of NEXT BIOMETRICS GP (Oslo Børs Benchmark Index_GI: NEXT.OL) rose by a staggering 27.92% in 21 sessions from kr4.19 to kr5.36 at 15:10 EST on Thursday, after two successive sessions in a row of losses. Oslo Børs Benchmark Index_GI is jumping 0.31% to kr1,207.72, following the last session's upward trend.

NEXT BIOMETRICS GP's last close was kr5.40, 9.7% below its 52-week high of kr5.98.

About NEXT BIOMETRICS GP

NEXT Biometrics Group ASA, through its subsidiaries, engages in the research, development, manufacture, and commercialization of fingerprint technology and products in Asia. The company offers fingerprint sensor modules and readers, flexible biometric subassemblies, and face recognition software, as well as software and hardware development kits for USB and SPI modules. Its products are used in point of sales terminals, smart card, government ID, access control, internet of things, and notebook applications. The company sells its sensors to distributors of electronic components. NEXT Biometrics Group ASA was incorporated in 2001 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, NEXT BIOMETRICS GP has a trailing twelve months EPS of kr-0.5.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -40.24%.

More news about NEXT BIOMETRICS GP (NEXT.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com